9club Forum

9club.com.

You are not logged in.

#1 2020-09-13 07:35:23

kubanpirapost
Member
Registered: 2020-09-13
Posts: 2

Predictive Analytics in MyRQBM® Portal – Part I

[email protected]

A Clinical Research Must-Have: Next Generation Predictive Analytics

Previous Next  A Clinical Research Must-Have: Next Generation Predictive  Analytics    The long-term bonus of process efficiencies in clinical trials.
In today’s fast-paced global economy, automated data analysis to optimize and accelerate working processes is common practice for most  financial data  providers (e.g.
Bloomberg,  Thomson Reuters ).
Due to the short analytical cycles that feed the financial news streams, the advantage of this approach can be experienced by their subscribers almost instantaneously.   Unlike the quick turnaround times in the financial world, it takes on average 16 years to evaluate a compound in clinical research – so the advantageous effects of using novel data  analytics  technologies in this area, are not immediately noticeable.
Obviously, these  technologies  ought to pay off handsomely in the long run, greatly benefiting those pharma and CRO companies which decided to invest in process efficiencies.

Predictive Analytics produces actionable data at an early stage

It all becomes clear if you think of a clinical trial as a ‘data  manufacturing ’ process.
In a nutshell, the two main tasks of clinical research  organization s are planning and implementing data collection and analysis.
During this complex process of data manufacturing, it is almost impossible to avoid data  integrity  issues.
Therefore, it makes sense to identify and report errors upon (early-)detection by use of automated  predictive  analytics  , so that undesirable trends can be corrected in a timely manner.
This improvement in process efficiency can help pharma  companies  and CROs become strong and competitive industry players.
Changing processes and  companies , a productive 5-year prospect.
Last April, the Institute for Human Data Science published a report on global trends in clinical trials “The Changing Landscape of Research and Development”, stating that  predictive analytics will drive drug development productivity:   “Ongoing changes in the clinical development process has led to a record number of drug approvals in 2018, with 59 novel treatments reaching patients in the  United States  alone.
Over the next five years, trial  productivity  will be heavily influenced by key trends including biomarkers, pre-screened patient pools, and predictive analytics”[i].
Supported by research  find ings:   “…the amount of time a drug has been tested in a patient population at time of approval — patient years at approval — is declining”.
In addition to the observed ongoing changes in the clinical development process, drug development companies are also changing: almost two-thirds of new drugs are patented by  so-called  Emerging Biopharma Companies (EBP).
EBPs are increasingly able bringing drugs to market without the  ass istance of large pharma companies.
In 2018, .

59 new active substances (NAS) were launched in the US

New drug approvals  are  now higher than any time in the last five years.
Most of the N ASs  (i.e.

38 drugs) were patented by EBP companies

of which 74% were also registered by these companies.
Pic 1.
Analytics maturity in Clinical Operations [ Link  to high res version here] A mindset evolution, from descriptive to predictive analytics.
Most industry researchers seem to be in  agreement  that the  duration and success of a modern clinical trial is influenced by eight key factors:   Application of digital health / mobile / smart technologies.
Emergence of curated real-world data sources.

Use of Predictive Analytics and Artificial Intelligence (AI)

Shifts in types of drugs being tested.
Availability of Biomarker test.
Shifts in the regulatory landscape.
Patient centricity and an increased focus on patient reported outcomes.
Availability of pools of pre-screened patients/direct-to-patient recruitment.
Current successful biopharma companies, that have embraced modern technological advancements, demonstrate that the first three factors contribute to the successful development of a sustainable model of New Active Substance generation.
Their living-in-the-present-moment mindset evolved from a descriptive analytics into predictive and prescriptive mindset of the future.
Predict and prescribe, act now shapes your future.
In summary, recent evidence of new domination of technology-driven biopharma companies demonstrates that automated, remote drug efficacy and safety data capture technologies, enable virtual trial formats and ease the workload burden of clinical sites.
Predictive Analytics and  centralized data management are seen as the next generation methodologies:  “growing across most therapy areas in the coming years”.
Pharma companies and CROs that embrace next generation analytics will position themselves for profitable competitive edge in the industry.
References.

[i] The Changing Landscape of Research and Development

Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity.
Institute Report.
April 23, 2019 //  https://www.iqvia.com/institute/reports/the-changing-landscape-of-research-and-development.
Read also:.
Predictive Analytics in MyRQBM® Portal – Part I.

Predictive Analytics in MyRBQM® Portal – Part II

By Artem Andrianov, Ph.
D.

MBA  2020-05-15T10:29:37+00:00 July 8

2019 0 Comments    Share This Story.

Email       About the Author: Artem Andrianov

Ph.
D., MBA.
Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology.
Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc.
10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry.
Life passion: improving clinical research with RbM.

Driving the RbM research to new frontiers for CROs

pharma and biotech companies.
Related Posts.
Optimization of eCOA Data Quality using Risk-Based Quality Management  Gallery    Optimization of eCOA Data Quality using Risk-Based Quality Management.
Q&A | Minds-On Impact COVID-19 on Clinical Trials  Gallery    Q&A | Minds-On Impact COVID-19 on Clinical Trials.
Coronavirus | COVID-19 RACT Now Available  Gallery    Coronavirus | COVID-19 RACT Now Available.
Coronavirus | What if you can no longer visit your sites.
Gallery    Coronavirus | What if you can no longer visit your sites.
Indication Focused RBQM for Rare Disease Drug Development  Gallery    Indication Focused RBQM for Rare Disease Drug Development.
Related Categories.
Blog (74).
Case Study (6).
Conferences (7).
Free Infographics for Clinical Experts (9).
Free White Papers for Clinical Experts (12).
Library (11).
Neat Features (11).
News (68).
RBM Product Updates (3).
Webinar (2).
Join our Community of Clinical Experts     Email Address     First Name    Last Name.

Offline

Board footer

Powered by FluxBB